Goldfinch Bio
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Goldfinch Bio developed investigational medicines for kidney diseases, including GFB-887 and GFB-024.
02 / Goldfinch Bio FAILURE REASONS
Failure reasons
Executives identified the inability to secure further financing as the reason for closing. The company had already reduced staff during 2022. Its lead program produced mixed results across kidney conditions, but the trial record attributed termination to business reasons rather than a confirmed safety failure.
03 / EVENT HISTORY
Events in the structured record
- Staff reductions and trial termination
The workforce was reduced during the year; the lead trial was terminated in November for business reasons.
- Company wind-down and asset process
In January executives confirmed closure and a creditor-benefit asset assignment process.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Further development required financing
- 02
Additional financing could not be secured
- 03
Staff and development activity reduced
- 04
Company wound down through an asset process